Flavia Biamonte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8735774/publications.pdf

Version: 2024-02-01

43 papers 2,584 citations

20 h-index 276539 41 g-index

45 all docs 45 does citations

45 times ranked 2888 citing authors

#	Article	IF	CITATIONS
1	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
2	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	3.3	263
3	Ferroptosis and Cancer: Mitochondria Meet the "lron Maiden―Cell Death. Cells, 2020, 9, 1505.	1.8	253
4	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
5	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
6	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
7	Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease. Cells, 2020, 9, 1558.	1.8	75
8	MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. Scientific Reports, 2019, 9, 5668.	1.6	74
9	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	3.3	66
10	Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. Oncotarget, 2016, 7, 62019-62033.	0.8	62
11	Iron Metabolism in the Tumor Microenvironmentâ€"Implications for Anti-Cancer Immune Response. Cells, 2021, 10, 303.	1.8	55
12	Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. Journal of Experimental and Clinical Cancer Research, 2017, 36, 104.	3 . 5	47
13	Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of miR-125b/p53 axis. Cell Death and Disease, 2018, 9, 1174.	2.7	44
14	H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-13.	1.9	41
15	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	0.6	34
16	shRNA targeting of ferritin heavy chain activates H19/miR-675 axis in K562 cells. Gene, 2018, 657, 92-99.	1.0	31
17	H-Ferritin-Regulated MicroRNAs Modulate Gene Expression in K562 Cells. PLoS ONE, 2015, 10, e0122105.	1.1	30
18	Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica, 2011, 96, 1398-402.	1.7	27

#	Article	IF	CITATIONS
19	H ferritin silencing induces protein misfolding in K562 cells: A Raman analysis. Free Radical Biology and Medicine, 2015, 89, 614-623.	1.3	26
20	Iron Administration Overcomes Resistance to Erastin-Mediated Ferroptosis in Ovarian Cancer Cells. Frontiers in Oncology, 2022, 12, 868351.	1.3	26
21	FTH1P3, a Novel H-Ferritin Pseudogene Transcriptionally Active, Is Ubiquitously Expressed and Regulated during Cell Differentiation. PLoS ONE, 2016, 11, e0151359.	1.1	25
22	FTH1 Pseudogenes in Cancer and Cell Metabolism. Cells, 2020, 9, 2554.	1.8	25
23	Ferritin Heavy Subunit Silencing Blocks the Erythroid Commitment of K562 Cells via miR-150 up-Regulation and GATA-1 Repression. International Journal of Molecular Sciences, 2017, 18, 2167.	1.8	24
24	Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. Journal of Translational Medicine, 2021, 19, 79.	1.8	24
25	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	3.3	22
26	Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. Journal of Experimental and Clinical Cancer Research, 2018, 37, 84.	3.5	20
27	Caffeine Positively Modulates Ferritin Heavy Chain Expression in H460 Cells: Effects on Cell Proliferation. PLoS ONE, 2016, 11, e0163078.	1.1	17
28	FtH-Mediated ROS Dysregulation Promotes CXCL12/CXCR4 Axis Activation and EMT-Like Trans-Differentiation in Erythroleukemia K562 Cells. Frontiers in Oncology, 2020, 10, 698.	1.3	17
29	Gene expression analysis of autofluorescence margins in leukoplakia and oral carcinoma: A pilot study. Oral Diseases, 2021, 27, 193-203.	1.5	14
30	Uncovering the Metabolic and Stress Responses of Human Embryonic Stem Cells to FTH1 Gene Silencing. Cells, 2021, 10, 2431.	1.8	14
31	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. Oncotarget, 2018, 9, 23960-23974.	0.8	13
32	Chemoresistance in H-Ferritin Silenced Cells: The Role of NF-κB. International Journal of Molecular Sciences, 2018, 19, 2969.	1.8	12
33	Human haematological and epithelial tumor-derived cell lines express distinct patterns of onco-microRNAs. Cellular and Molecular Biology, 2017, 63, 75.	0.3	12
34	COVID-19: High-JAKing of the Inflammatory "Flight―by Ruxolitinib to Avoid the Cytokine Storm. Frontiers in Oncology, 2020, 10, 599502.	1.3	9
35	Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing home of Southern Italy. Infection, Genetics and Evolution, 2022, 99, 105253.	1.0	5
36	The <scp><i>ERCC2</i> G</scp> ln/ <scp>G</scp> ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	1,2	4

#	Article	IF	CITATIONS
37	Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. Annals of Hematology, 2014, 93, 523-524.	0.8	4
38	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. Blood, 2011, 118, 2811-2811.	0.6	4
39	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
40	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	0.6	2
41	Gene Expression Profiles in Surgical Excision Margins Detected by Tissue Auto-Fluorescence (VELscopeâ,,¢) in Oral Potentially Malignant Disorders (OPMDs) and Oral Squamous Cell Carcinoma (OSCC). Proceedings (mdpi), 2019, 35, .	0.2	O
42	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	0.6	0
43	Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis. Blood, 2013, 122, 4058-4058.	0.6	0